Drug Profile
Research programme: melanoma vaccine - MaxCyte
Alternative Names: Melanoma immunotherapy - MaxCyte; Melanoma vaccine research programme - MaxCyteLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MaxCyte
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 15 Apr 2004 Preclinical trials in Malignant melanoma in USA (unspecified route)